• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

tetano

Editor, Senior Moderator
Hum Vaccin Immunother


. 2022 Jun 15;2082191.
doi: 10.1080/21645515.2022.2082191. Online ahead of print.
Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice


Leonard Moise[SUP] 1 2 [/SUP], Lauren M Meyers[SUP] 1 [/SUP], Hyesun Jang[SUP] 2 [/SUP], Mayara Grizotte-Lake[SUP] 1 [/SUP], Christine M Boyle[SUP] 1 [/SUP], Bethany McGonnigal[SUP] 1 [/SUP], Pan Ge[SUP] 2 [/SUP], Ted M Ross[SUP] 2 3 [/SUP], Anne S De Groot[SUP] 1 2 [/SUP]



Affiliations

Abstract

Strategies that improve influenza vaccine immunogenicity are critical for the development of vaccines for pandemic preparedness. Hemagglutinin (HA)-specific CD4[SUP]+[/SUP] T cell epitopes support protective B cell responses against seasonal influenza. However, in the case of avian H7N9, which poses a pandemic threat, HA elicits only weak neutralizing antibody responses in infection and vaccination without adjuvant. We hypothesized that an immune-engineered H7N9 HA incorporating a broadly reactive H3N2 HA-specific memory CD4[SUP]+[/SUP] T cell epitope that replaces a regulatory T cell-inducing epitope at the corresponding position in H7N9 HA could harness preexisting influenza T cell immunity to increase CD4[SUP]+[/SUP] T cells that are needed for protective antibody development. We designed and produced a virus-like particle (VLP) vaccine that carries the epitope augmented H7N9 HA (OPT1) and immunized HLA-DR3 transgenic mice with established H3N2 immunity. OPT1-VLPs stimulated higher stem cell, central, and effector memory CD4[SUP]+[/SUP] T cell levels over wild type VLP immunization. In addition, activated, IL-21-producing follicular helper T cell frequencies were enhanced. This novel immunogen design strategy illustrates that site-specific modifications aimed to augment T cell epitope content enhance CD4[SUP]+[/SUP] T cell responses among critical subpopulations capable of aiding protective immune responses upon antigen re-encounter and that mobilization of immune memory can be used to overcome the poor immunogenicity of avian influenza viruses.

Keywords: H7N9; T cell; T cell epitope; Vaccine; hemagglutinin; immunoinformatics; influenza; virus-like particle.
 
Back
Top Bottom